Skip to main content
Contact Us
Subscribe
E-Edition
71°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by AstraZeneca
< Previous
1
2
3
4
5
6
7
Next >
LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial
June 03, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial
June 02, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
June 01, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
May 26, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
May 25, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
New AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD
May 23, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial
May 17, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients
May 09, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks
April 24, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial
April 16, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca reinforces commitment to advancing science for patients with chronic kidney disease and hyperkalemia at NKF Spring Clinical Meeting 2023
April 11, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
March 27, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
March 09, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer
March 09, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
March 06, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
March 02, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium
February 16, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TEZSPIRE® approved for self-administration in the US with a new pre-filled pen
February 02, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
January 23, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AIRSUPRA™ (PT027) approved in the US for asthma
January 11, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Awards $4M to Nonprofit Organizations to Advance Health Equity
December 13, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)
December 08, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer
December 08, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
December 07, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022
November 30, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022
November 22, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
November 11, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022
November 10, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
November 09, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer
October 26, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.